Treatment of Ankylosing Spondylitis with Biologic Agents

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Treatment of Ankylosing Spondylitis with Biologic Agents

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 9(1): 35-40.

Author(s): Mehmet Tuncay Duruoz.

Affiliation: CBU Medical School, PMR Department, Rheumatology Division, Manisa, Turkey.


Ankylosing spondylitis (AS) is a chronic inflammatory disorder of the spine that can lead to significant disability if left untreated. Although conventional treatments can be successful in alleviating symptoms, they have not been shown to stop progression of the disease. The proinflammatory cytokine tumor necrosis factor (TNF) is central to the pathogenesis of AS. Several TNF-α blocker drugs such as infliximab, adalimumab, etanercept and golimumab have been developed and shown to control symptoms effectively, possibly preventing both clinical and radiographic progression of the disease in patients with AS. Acute inflammatory lesions in the spine and sacroiliac joints can be effectively suppressed by the TNF-α blockers in AS, suggesting that bone destruction and bone proliferation might be prevented.


Ankylosing spodylitis, biologic agents, TNF blockers, treatment.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 1
First Page: 35
Last Page: 40
Page Count: 6
DOI: 10.2174/187152310790711674

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science